Cryo-Cell International, Inc. (NYSEARCA:CCEL) reported financial results for the fiscal second quarter of 2026 on Tuesday after the market close, delivering a mild earnings surprise but seeing its shares dip in after-hours trading.
The company posted net income of $555,000, or $0.07 per share, on revenue of $7.8 million for the three months ended May 31, 2026. Analysts had expected revenue of approximately $7.70 million, placing the actual figure roughly 1% above consensus. On the earnings line, analysts projected $0.00 per share, while the company delivered $0.07.
Because the revenue deviation sits below the 2% threshold, the top-line performance is best characterized as inline with expectations. However, the swing to profitability from a zero EPS estimate marks a clear positive surprise compared to the consensus view.
Business Update and Key Metrics
Cryo-Cell, recognized as the world’s first private cord blood bank, operates through three segments: family-use cellular processing and storage, the manufacture of its proprietary PrepaCyte-CB processing technology, and public banking services in partnership with Duke University.
Revenue slipped 2% year-over-year from $7.9 million in the prior-year quarter. The breakdown showed $7.71 million in processing and storage fees, $46,000 in public banking revenue, and $14,000 in product revenue. This compares with $7.87 million, $43,000, and $14,000, respectively, in the same quarter of fiscal 2025. The slight decline in processing and storage fee revenue was the primary driver of the overall drop.
Net income improved markedly, rising to $555,000 from $356,000 in the year-ago period. The company did not provide explicit forward guidance in the press release. The lack of an outlook is treated as a neutral factor for market interpretation and does not explain the negative after-hours price action.
Market Reaction and Price Context
Despite the earnings beat, shares currently trade down approximately 4.8% in after-hours activity. This negative reaction suggests that investors may be focusing on the year-over-year revenue contraction rather than the earnings surprise, or that expectations for the upcoming quarters are tempering optimism.
Near-term price trends offer a mixed picture. Over the past week, the stock has fallen about 4.8%. That decline reverses a 2.4% gain over the trailing two-week period and follows a monthly drop of roughly 4.5%. The after-hours selloff adds to the recent negative momentum, indicating that the market may be discounting the quarter’s results or positioning for softer demand.
Outlook and Estimates
Looking ahead, analysts project a modest sequential step-up for the fiscal third quarter. The consensus revenue estimate for Q3 2026 stands at $7.60 million. For the full fiscal year 2026, analysts forecast total sales of $30.64 million and earnings per share of $0.08. The company’s current run rate, if maintained, suggests it may need stronger performance in the back half of the year to reach those analyst expectations.
For a deeper look into historical earnings trends, future projections, and detailed analyst estimates, you can view the full Cryo-Cell earnings history and forecasts at the earnings page and the analyst ratings and forecast page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making any trading decisions.
Read full article here »
View the Zacks #1 Rank List
Cryo-Cell International (NYSEARCA:CCEL) Shares Dip on Mixed Quarter Despite Earnings Beat
Cryo-Cell International, Inc. (NYSEARCA:CCEL) reported financial results for the fiscal second quarter of 2026 on Tuesday after the market close, delivering a mild earnings surprise but seeing its shares dip in after-hours trading.
The company posted net income of $555,000, or $0.07 per share, on revenue of $7.8 million for the three months ended May 31, 2026. Analysts had expected revenue of approximately $7.70 million, placing the actual figure roughly 1% above consensus. On the earnings line, analysts projected $0.00 per share, while the company delivered $0.07.
Because the revenue deviation sits below the 2% threshold, the top-line performance is best characterized as inline with expectations. However, the swing to profitability from a zero EPS estimate marks a clear positive surprise compared to the consensus view.
Business Update and Key Metrics
Cryo-Cell, recognized as the world’s first private cord blood bank, operates through three segments: family-use cellular processing and storage, the manufacture of its proprietary PrepaCyte-CB processing technology, and public banking services in partnership with Duke University.
Revenue slipped 2% year-over-year from $7.9 million in the prior-year quarter. The breakdown showed $7.71 million in processing and storage fees, $46,000 in public banking revenue, and $14,000 in product revenue. This compares with $7.87 million, $43,000, and $14,000, respectively, in the same quarter of fiscal 2025. The slight decline in processing and storage fee revenue was the primary driver of the overall drop.
Net income improved markedly, rising to $555,000 from $356,000 in the year-ago period. The company did not provide explicit forward guidance in the press release. The lack of an outlook is treated as a neutral factor for market interpretation and does not explain the negative after-hours price action.
Market Reaction and Price Context
Despite the earnings beat, shares currently trade down approximately 4.8% in after-hours activity. This negative reaction suggests that investors may be focusing on the year-over-year revenue contraction rather than the earnings surprise, or that expectations for the upcoming quarters are tempering optimism.
Near-term price trends offer a mixed picture. Over the past week, the stock has fallen about 4.8%. That decline reverses a 2.4% gain over the trailing two-week period and follows a monthly drop of roughly 4.5%. The after-hours selloff adds to the recent negative momentum, indicating that the market may be discounting the quarter’s results or positioning for softer demand.
Outlook and Estimates
Looking ahead, analysts project a modest sequential step-up for the fiscal third quarter. The consensus revenue estimate for Q3 2026 stands at $7.60 million. For the full fiscal year 2026, analysts forecast total sales of $30.64 million and earnings per share of $0.08. The company’s current run rate, if maintained, suggests it may need stronger performance in the back half of the year to reach those analyst expectations.
For a deeper look into historical earnings trends, future projections, and detailed analyst estimates, you can view the full Cryo-Cell earnings history and forecasts at the earnings page and the analyst ratings and forecast page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making any trading decisions.
Read full article here »